OLMA trades 261.7% below Wall Street's consensus target of $41.20.
Last 12 months price action with 12-month analyst target path
The base valuation assumes OLMA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 29, 2026, Olema Pharmaceuticals, Inc. (OLMA) has a Wall Street consensus price target of $41.20, based on estimates from 8 covering analysts. With the stock currently trading at $11.39, this represents a potential upside of +261.7%. The company has a market capitalization of $995M.
Analyst price targets range from a low of $35.00 to a high of $48.00, representing a 32% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, OLMA trades at a trailing P/E of -6.1x. Analysts expect EPS to grow -23.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SRRKScholar Rock Holding Corporation | $6.6B | $54.76 | $59.17 | +8.1% | Buy | — | 12 |
KYMRKymera Therapeutics, Inc. | $8.8B | $108.12 | $123.50 | +14.2% | Buy | — | 26 |
RVMDRevolution Medicines, Inc. | $38.7B | $182.08 | $165.75 | -9.0% | Buy | — | 22 |
PRAXPraxis Precision Medicines, Inc. | $9.5B | $327.79 | $584.00 | +78.2% | Buy | — | 16 |
NUVLNuvalent, Inc. | $9.1B | $123.52 | $127.32 | +3.1% | Hold | — | 18 |
TNGXTango Therapeutics, Inc. | $3.7B | $31.47 | $46.00 | +46.2% | Buy | — | 13 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.00 | $31.00 | +0.0% | Buy | — | 18 |
ARVNArvinas, Inc. | $516M | $8.00 | $14.75 | +84.4% | Buy | — | 26 |
ORICORIC Pharmaceuticals, Inc. | $987M | $9.53 | $19.25 | +102.0% | Buy | — | 10 |
PTGXProtagonist Therapeutics, Inc. | $7.8B | $121.88 | $117.25 | -3.8% | Buy | 30.2x | 26 |
Quick answers to the most common questions about buying OLMA stock.
The consensus Wall Street price target for OLMA is $41.2, representing 261.7% upside from the current price of $11.39. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
OLMA has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $41.2 implies 261.7% upside from current levels.
OLMA's current price is $11.39 with a consensus target of $41.2 (261.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $48 for OLMA, while the most conservative target is $35. The consensus of $41.2 represents the median expectation. These targets typically reflect 12-month expectations.
OLMA is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month OLMA stock forecast based on 8 Wall Street analysts shows a consensus price target of $41.2, with estimates ranging from $35 (bear case) to $48 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on OLMA, with a "Buy" consensus rating and $41.2 price target (261.7% upside). 8 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
OLMA analyst price targets range from $35 to $48, a 32% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $41.2 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.